KRAS vaccine for pancreatic cancer triggered T cells in 99%

A KRAS vaccine for pancreatic cancer generated a mutant-KRAS-specific immune response in 89 of 90 patients whose T cells could be evaluated. Nearly 99% sounds close to a perfect result. But the clinical part of the trial tells a more complicated story: the vaccine did not meet the study's primary efficacy endpoint.

That tension is what makes the phase 2 AMPLIFY-7P trial, published in Nature Medicine, particularly informative. It separates two questions that are easy to blur together. Can a vaccine teach the immune system to recognize a pancreatic tumor target? And has that immune response already been shown to reduce the risk of cancer returning?

Seven KRAS mutations as targets

Pancreatic ductal adenocarcinoma remains particularly difficult to treat once it spreads, and recurrence is common even after surgery. KRAS is an unusually attractive molecular target because mutations in the gene occur in roughly 90–95% of pancreatic ductal adenocarcinomas.

The experimental vaccine, called camupepimut or ELI-002 7P, contains peptides representing seven common mutant forms of KRAS: G12D, G12R, G12V, G12A, G12C, G12S and G13D.

Its design also addresses a practical problem with peptide vaccines: getting enough antigen to the lymph nodes, where adaptive immune responses are organized.

The vaccine components carry lipid modifications that bind albumin. This promotes transport through lymphatic vessels and accumulation in lymph nodes, where antigen-presenting cells can activate and expand T cells capable of recognizing mutant KRAS.

AMPLIFY-7P was an open-label randomized phase 2 trial involving 144 patients with stage I–III KRAS-mutant pancreatic cancer. All had undergone pancreatic resection and chemotherapy and had no radiographically detectable recurrence when they entered the trial.

Ninety-six patients were assigned to camupepimut and 48 to observation. Median follow-up at the data cutoff was 19.4 months.

A remarkably consistent immune response

The immunology result was striking.

Of the 96 vaccinated patients, 90 had samples suitable for evaluating immunogenicity. Eighty-nine of those 90, or 98.9%, developed a mutant-KRAS-specific T-cell response after vaccination.

The median increase from baseline was 44.3-fold. In 74 of 90 patients, or 82.2%, the response increased by more than 9.17-fold — a threshold previously associated with better outcomes in an earlier trial of the same vaccine platform.

There was another important layer to the result. Camupepimut contains seven KRAS antigens, while an individual tumor carries a particular KRAS mutation. Among the 89 immune responders, 78 developed T-cell responses against the specific KRAS mutation found in their own tumor.

This is strong evidence of immunogenicity. The vaccine can generate the kind of tumor-directed T-cell response it was designed to produce.

But immunogenicity is not the same as demonstrated clinical efficacy.

Why 99% immune response did not mean 99% clinical success

The trial's primary question was whether camupepimut improved disease-free survival compared with observation.

It did not meet the prespecified threshold for success.

Median disease-free survival was 23.8 months in the vaccine group and 21.2 months in the observation group, with a hazard ratio of 0.85 and P=0.5329. On the primary analysis, therefore, the trial did not establish that vaccination reduced the risk of recurrence or death.

There were encouraging signals elsewhere in the data.

During the first six months, 75.7% of vaccinated patients remained disease-free compared with 61.7% in the observation group, a difference of 14 percentage points. The corresponding exploratory analysis nevertheless fell short of conventional statistical significance.

Prespecified subgroup analyses also suggested a benefit among patients who were negative for circulating tumor DNA at baseline and among those who had not previously received radiotherapy.

Perhaps the most intriguing observation came from the immune-response data. Within the vaccinated group, patients whose mutant-KRAS-specific T-cell responses rose by more than 9.17-fold had substantially better disease-free survival than weaker responders.

That association is biologically compelling, but it is not equivalent to a randomized demonstration that the stronger immune response caused the better outcome. Immunogenicity-outcome analyses were confined to vaccinated patients, and people who mount particularly strong T-cell responses may differ from weaker responders in other relevant ways.

The trial also had important limitations. It was open-label and modest in size. Subgroup and exploratory immunogenicity analyses were not adjusted for the multiplicity of comparisons. A post hoc multivariable analysis produced a more favorable estimate for camupepimut after accounting for baseline imbalances, but the authors appropriately describe that result as hypothesis-generating. Overall-survival data are not yet mature.

The study was sponsored and funded by Elicio Therapeutics and was designed by the company in collaboration with academic investigators.

Safety did not show an obvious disadvantage for the vaccine. Grade 3 or higher adverse events occurred in 10.4% of camupepimut-treated patients and 14.6% of those assigned to observation.

AMPLIFY-7P therefore resists a simple headline. It cannot be summarized accurately as a vaccine that “worked in 99% of patients,” because that number describes an immune response, not prevention of recurrence. But neither is the study simply negative: it demonstrated that a lymph-node-targeted vaccine can generate mutant-KRAS-specific T cells in almost every evaluable recipient.

The next test is harder. A confirmatory phase 3 program is planned to determine whether this unusually consistent immune response can be converted into a reproducible clinical reduction in pancreatic-cancer recurrence, potentially using a refined dosing strategy and combinations with other immunotherapies.